September 17, 2014
London, United Kingdom
Following on the inventive step vs. obviousness webinar from earlier this year, this seminar will focus specifically on the chemical, biotechnology and pharmaceutical industries.
The requirements for inventive step in Europe and non-obviousness in the United States have many similarities but also some subtle differences. In most cases, you might expect similar results, but in some cases, you can end up with very different and unexpected outcomes. With global patenting strategies, companies often struggle to ensure consistency when prosecuting applications to grant in both jurisdictions. In this seminar, we shall look closely at obviousness at the U.S. Patent and Trademark Office (USPTO), inventive step at the European Patent Office (EPO), how they are both assessed and how objections can be overcome in the chemical, pharmaceutical, and biotechnology areas. Our panel will explore:
The panel will also discuss some of the techniques and strategies they have successfully implemented for patenting chemical and life sciences inventions, often in crowded art fields, including:
Admission is free, but space is limited. Please register by 12 September.
Moderator:
Anthony C. Tridico, Ph.D.
Speakers:
Bryan C. Diner
Erin M. Sommers, Ph.D.
Leythem A. Wall
Wednesday, 17 September 2014
12:30 - 13:00 - Registration
13:00 - 16:00 - Program
16:00 - 17:00 - Reception
Finnegan
16 Old Bailey
London EC4M 7EG
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.